All In Biotech

Drug Trial Radar · NCT06754852

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Feb 6, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Hemab ApSIndustry
Sponsor type
Industry
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy. Part C will evaluate the safety, PK, and PD of a single concomitant dose of HMB-002 and factor concentrate with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII who use factor concentrate as prophylaxis.

Conditions

  • Von Willebrand Disease (VWD)
  • Von Willebrand Disease (VWD), Type 1
  • Von Willebrand Disease (VWD), Type 2
  • Von Willebrand Disease (VWD), Type 3

Interventions

  • HMB-002 (Part A)Drug

    HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.

  • HMB-002 (Part B)Drug

    HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.

  • HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)Drug

    HMB-002 will be administered as a single dose with a concomitant single dose of factor concentrate. The planned duration of study participants in Part C will be approximately 17 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment emergent adverse events (TEAE)Time frame: up to Day 113

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Not yet recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Not yet recruiting

  • Children's Hospital of Los Angeles

    Los Angeles, California · Not yet recruiting

  • University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center

    Miami, Florida · Not yet recruiting

  • Emory Children's Center

    Atlanta, Georgia · Not yet recruiting

  • Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center

    Indianapolis, Indiana · Recruiting

  • Tulane University School of Medicine

    New Orleans, Louisiana · Not yet recruiting

  • University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders

    Ann Arbor, Michigan · Not yet recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Not yet recruiting

  • Oregon Health & Science University

    Portland, Oregon · Not yet recruiting

  • Hemophilia Center of Western Pennsylvania

    Pittsburgh, Pennsylvania · Not yet recruiting

  • The University of Texas Southwestern Medical Center

    Dallas, Texas · Not yet recruiting

  • Washington Institute For Coagulation (WIC)

    Seattle, Washington · Not yet recruiting

  • Fiona Stanley Hospital

    Murdoch, Perth, Australia · Not yet recruiting

  • Royal Prince Alfred Hospital

    Camperdown, Sydney, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom · Not yet recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • St James's University Hospital, Leeds Haemophilia Centre

    Leeds, United Kingdom · Not yet recruiting

  • Royal Liverpool and Broadgreen University Hospitals NHS TRUST, The Roald Dahl Haemostasis and Thrombosis Centre

    Liverpool, United Kingdom · Not yet recruiting

  • Richmond Pharmacology

    London, United Kingdom · Recruiting

  • St Thomas' Hospital

    London, United Kingdom · Not yet recruiting

  • Basingstoke and North Hampshire Hospital

    Basingstoke, Hampshire, United Kingdom · Recruiting

  • St George's Hospital

    Tooting, London, United Kingdom · Not yet recruiting

  • Royal London Hospital

    Whitechapel, London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.